Sorry, you need to enable JavaScript to visit this website.

The Sinopharm Vaccine Begins Production In The UAE

It’s now called Hayat-Vax!

Partnering up with China, the UAE will now be producing the COVID-19 Sinopharm vaccine domestically. As announced by Sheikh Abdullah bin Zayed, Minister of Foreign Affairs and International Cooperation on Sunday 28th March 2021, a vaccine deal has been signed with China’s Foreign Ministers, Wang Yi, and will be pioneered by Abu Dhabi’s Group 42, in conjunction with Chinese pharmaceutical company, Sinopharm.

The vaccine has already begun production within the UAE at pharmaceutical manufacturer Julphar’s plant in Ras Al Khaimah. The Emirati pharma company is not only producing the Sinopharm vaccine, but is also rebranding it and changing its name to Hayat-Vax. In Arabic, the word ‘hayat’ translates to ‘life’ and could be produced in quantities of over 2 million doses per month.
Hayat-Vax is the exact same as Sinopharm’s CNBG’s BiBP inactivated vaccine that was first administered to frontline workers by the UAE Ministry of Health and Prevention on December 9, 2020.

At the inauguration of the production of the Hayat-Vax, Sheikh Abdullah bin Zayed said, “Life sciences and vaccine manufacturing in our country is UAE’s contribution towards global efforts to address the Covid-19 pandemic that has affected the whole world.” He added: “The joint project is an added value to the international efforts being made in the face of the Covid-19 crisis, which has been taking a toll on everyday lives across the world.”

52% of the UAE’s population has already been vaccinated with approved vaccines such as Sinopharm, Pfizer-BioNTech, and Oxford AstraZeneca. 

Share Article

Write a comment